Methods Development for Measurement of Environmental Exposures of Diabetes and Diabetes-related Outcomes

Ana Navas-Acien, MD, PhD
Environmental Health Sciences
Johns Hopkins Bloomberg School of Public Health
Diabetes

• Group of metabolic diseases characterized by hyperglycemia due to β-cell dysfunction, insulin resistance, or both that results in long-term complications
  • Type 1 Diabetes
  • Type 2 Diabetes (90-95% of all cases, in particular in adult populations)
  • Gestational Diabetes

• Pre-diabetes: impaired fasting glucose (fasting plasma glucose levels 100 to 125 mg/dl), or impaired glucose tolerance (2-h values in the oral glucose tolerance test of 140 to 199 mg/dl), or hemoglobin A1C levels of 5.7 to 6.4% are defined as having pre-diabetes (ADA guidelines)
Outcome ascertainment

- Based on established clinical guidelines (e.g. American Diabetes Association)
  1. Hemoglobin A1C ≥ 6.5% using a method certified and standardized to the Diabetes Control and Complication Trial (DCCT) assay OR
  2. Fasting plasma glucose ≥ 126 mg/dl. No caloric intake for at least 8 h OR
  3. 2-hour plasma glucose ≥ 200 mg/dl during an oral glucose tolerance test (OGTT) OR
  4. In a patient with classic symptoms of hypergluceremia or hyperglycemic crisis, a random plasma glucose ≥ 200 mg/dl (11.1 mmol/l)

For clinical purposes, in the absence of unequivocal hyperglycemia, criteria 1-3 should be confirmed by repeat testing.

Diabetes outcome definition

- Very good:
  - ADA definition without repeated measures
  - Self-reported physician diagnosis

- Good / Adequate:
  - ADA definition without repeated measures and no other information provided on fasting and assays
  - Use of medical records with details on criteria used

- Limited:
  - Use of medical records without details on criteria used

- Deficient:
  - Unclear questions or information used
  - Glucosuria
  - Diabetes mortality
Diabetes related outcomes

• Measures of glycemia: fasting plasma glucose or hemoglobin A1c (no fasting required)
  - Persons without diabetes: inform on future risk
  - Persons with diabetes: informs on diabetes control
  - Analyses need to be stratified by diabetes status

• Insulin and its related measures based on the homeostatic model assessment (HOMA) of insulin resistance (HOMA-IR) and β-cell function (HOMA-β)
  - HOMA measures, especially HOMA-IR, are preferred versus insulin for epidemiological research
  - Analyses need to be restricted to participants without diabetes
## Diabetes related outcomes

- **Metabolic syndrome**
  - Clustering of biochemical and physiological abnormalities in triglycerides, waist circumference, blood pressure, cholesterol and fasting glucose
  - **ATP III definition**: 3 of 5 components need to be present

<table>
<thead>
<tr>
<th>Component</th>
<th>Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Waist circumference</td>
<td>Men: &gt; 102 cm, Women: &gt; 88 cm</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>≥150 mg/dL</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>Men: &lt;40 mg/dL, Women: &lt;50 mg/dL</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>≥130 / ≥ 85 mmHg</td>
</tr>
<tr>
<td>Fasting blood glucose</td>
<td>≥110 mg/dL</td>
</tr>
</tbody>
</table>

*National Cholesterol Education Program’s Adult Treatment Panel III (ATP III)*
Methodological considerations

- Prospective cohort design

- Participants at risk of developing the disease (diabetes-free of appropriate age range)

- Sensitivity analyses excluding participants with pre-diabetes, especially for biomarkers of environmental exposures, as pre-diabetes could affect the biomarker toxicokinetics

- Adequate follow-up:
  - Long-latency (early life exposures)
  - Short-latency (similar to BMI)
Confounding

• Biological consideration
  - Age, sex, SES, lifestyle factors
  - Body mass index (careful thinking regarding its possible role as mediator) and other measures of adiposity

• Unadjusted / minimally adjusted and progressively adjusted results

• Discussion about residual and unmeasured confounding
Analysis (beyond confounding)

- Description information by disease status and exposure levels
- Report participants with missing data and strategy to deal with it
- Evaluation of model assumptions
- Evaluation of non-linear exposure-responses
- Evaluation of effect modification conducted with an a-priori rationale or a sensitivity analysis to evaluate the consistency of the findings by participants' characteristics
- Analysis of insulin and HOMA restricted to participants without diabetes
- Analysis of glycemia should be stratified by diabetes-status
- Sensitivity analysis excluding participants with pre-diabetes
Acknowledgements

Diabetes working group

- Robin Puett       University of Maryland
- Glinda Cooper    EPA
- Audrey Galizia   EPA
- Amanda Persad    EPA
- Michelle Cawley  ICF